Amanote Research
Register
Sign In
Successful Treatment of Newly Diagnosed POEMS Syndrome With Reduced-Dose Bortezomib Based Regimen
British Journal of Haematology
- United Kingdom
doi 10.1111/bjh.14497
Full Text
Open PDF
Abstract
Available in
full text
Categories
Hematology
Date
February 1, 2017
Authors
Haiyan He
Weijun Fu
Juan Du
Hua Jiang
Jian Hou
Publisher
Wiley
Related search
Peripheral Neuropathy Induced by Subcutaneous Bortezomib-Based Induction Therapy for Newly Diagnosed Multiple Myeloma
Haematologica
Hematology
High-Dose BCNU/Melphalan Conditioning Regimen Before Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma
Bone Marrow Transplantation
Transplantation
Hematology
Efficacy and Safety of Reduced-Intensity Induction Therapy With a Bortezomib-Based Regimen in Elderly Patients With Multiple Myeloma
Therapeutic Advances in Hematology
Hematology
Elderly Do Benefit From Induction Chemotherapy: High Dose Mitoxantrone Based (“5+1”) Induction Chemotherapy Regimen in Newly Diagnosed Acute Myeloid Leukemia
American Journal of Hematology
Hematology
Conservative Treatment of Newly Diagnosed Keratoconus
Acta Ophthalmologica
Medicine
Ophthalmology
Efficacy of Bortezomib in Refractory Form of Multicentric Castleman Disease Associated to Poems Syndrome (MCD-POEMS Variant)
Annals of Hematology
Medicine
Hematology
Decision Aids Reduced Decisional Conflict in Patients With Newly Diagnosed Hypertension
Evidence-Based Medicine
Medicine
Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients: A Single-Center Experience With a Bortezomib-Based Regimen
Experimental and Clinical Transplantation
Transplantation
A Fludarabine-Based Dose-Reduced Conditioning Regimen Followed by Allogeneic Stem Cell Transplantation From Related or Unrelated Donors in Patients With Myelodysplastic Syndrome
Bone Marrow Transplantation
Transplantation
Hematology
